Flow cytometry monitoring of dogs with B cell lymphoma

Golden retriever close up
Species:
Dog

Category:
Cancer/Oncology

Status: Open and enrolling
Principal Investigator: 
Amber Wolf-Ringwall
DVM, PhD
Assistant Professor
Jack O'Day
DVM
Resident
Co-Investigator: 
Jessica Lawrence
DVM, DACVIM, DACVR, DECVDI
Davis Seelig
DVM, PhD, DACVP
Contact:

Dr. O'Day
[email protected]

Dr. Wolf-Ringwall
[email protected]

I'm Interested

Study title

Quantitative flow cytometric monitoring for remission status in canine B cell lymphoma: a pilot study

Purpose of study

B-cell lymphoma is the most common blood cancer of dogs, and despite high rates of remission with conventional chemotherapy, most dogs will eventually develop disease relapse.  For this reason, we hope to better understand the remission status of dogs undergoing chemotherapy for high-grade, multicentric B-cell lymphoma at a molecular level using flow cytometry.

Eligibility criteria

  • Dogs diagnosed (cytologically or histologically) with high-grade, multicentric B-cell lymphoma that intend to undergo chemotherapy
  • Pursuing chemotherapy treatment with UMN-VMC Oncology Service

Procedures

  • Lymph node sampling and blood collection for flow cytometry and cytology at regular, pre-determined timepoints during chemotherapy
  • Re-check physical examinations, complete blood counts and lymph node/blood sampling every month until clinical relapse after completion of chemotherapy protocol

Costs

  • Study covers the cost of re-check examinations (physical exam and oncology consultation), complete blood counts, and lymph node and blood sampling for flow cytometry every 4 weeks after completion of chemotherapy protocol
  • Study covers cost of all sampling during chemotherapy
  • Owners are responsible for the majority of costs of chemotherapy medications and recheck examinations during chemotherapy treatment